Accelerating Global Access to Gene Therapies: Case Studies from Lowand Middle-Income Countries

whitePaper | June 8, 2022

Sequencing of human genomes is fast becoming an affordable technology for general consumer.

whitePaper | December 14, 2022

Within the drug development process, there are several steps that occur between the laboratory and final manufacture of the drug product.

whitePaper | November 4, 2019

Revenues from biologics increased by 70% from 2011 to 2016. Biologics account for 20-22% of total pharmaceutical spending. IQVIA estimates US biologics spending will reach $320bn by 2023

whitePaper | June 23, 2022

Cell and gene therapies require both efficient and reliable freeze-thaw systems. Building the most effective system depends on selecting the right materials and instruments.

whitePaper | March 30, 2023

The discovery of nitrosamine genotoxins in several pharmaceuticals has led to monitoring and re-evaluation of manufacturing practices for those products considered atrisk.

whitePaper | March 24, 2023

Biotechnology companies are at the epicenter of innovative drug development, with discoveries spanning from small molecules, large molecules, and biologics to genomic medicines and first-inclass immunotherapies.